Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
hepatitis B
Biotech
Ascletis pulls FXR agonist from pipeline over phase 2 data
Ascletis has been developing ASC42 in a raft of conditions ranging from primary biliary cholangitis to metabolic-associated steatohepatitis.
James Waldron
Apr 3, 2024 8:50am
Altimmune bails on hepatitis B after phase 2 data disappoint
Mar 27, 2024 7:57am
Brii punts HIV, depression, lung programs to potential partners
Mar 22, 2024 11:34am
Roche grows hepatitis diagnostics roster with new immunoassays
Nov 27, 2023 10:26am
Hepatitis B drug developers chart slow progress, just like hep C
Nov 14, 2023 9:05am
Vaccitech reemerges as Barinthus with hep B data
Nov 10, 2023 9:30am